Abstract
Stroke is a major cause of death and disability, and it consumes a large proportion of health resources. Numerous treatments have been suggested for acute ischemic stroke but so far none has been shown to be effective in large randomized controlled trials. Thrombolytic treatment, which is so effective in acute myocardial infarction, has been evaluated in numerous individual stroke patients and some small pilot studies. Its efficacy now needs to be tested in a large multicenter trial.
Presented by L. Candelise, Istituto di Clinica Neurologica, Università degli Studi di Milano, Milano, Italy
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico: GISSI-2 (1990) A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infaction. Lancet 336:65–70
Antiplatelet Trialist’s Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 296:320–331
Brott T, Haley C, Levy D, et al (1990) Safety and potentional efficacy of tissue plasminogen activator (tPA) for stroke (Abstract). Stroke 2:181
Candelise L, Pinardi G, Aritzu E (1990) Stroke disability assessed by telephone interview: Reliability and reproducibility (Abstract). J Neurol 237:143
del Zoppo GJ (1988) Thrombolytic therapy in cerebrovascular disease. Stroke 19:1174–1179
del Zoppo GJ, Poeck K, Pessin MS, and 16 coauthors of the rt-PA Acute Stroke Study Group (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32:78–86
ISIS-2 (Second International Study of Infarct Survival Collaborative Group) (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction. Lancet 13:349–360
ISIS-3 (Third International Study of Infarct Survival Collaborative Group) (1992) A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin among 41, 299 cases of suspected acute myocardial infarction. Lancet 339:753–770
Italian Acute Stroke Study Group (L.Candelise principal investigator) (1988) Haemodilution in acute stroke: Results of the Italian haemodilution trial. Lancet 1:318–321
Sloan MA (1987) Thrombolysis and stroke: Past and future. Arch Neurol 44:748–768
Sundt T, Sharbrough F, Anderson R, Michenfelder J (1974) Cerebral blood flow measurements and electroencephalograms during carotid endarterectomy. J Neurosurg 41:310–320
The International Study Group (1990) In-hospital mortality and clinical course of 20, 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336:71–75
von Kummer R, Hutschenreuter M, Wildemann B, Hacke W (1989) Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in acute occlusions of intracranial arteries. J Cereb Blood Flow Metab 9(Suppl):5721
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
del Zoppo, G.J., Mori, E., Hacke, W. (1993). Thrombolytic and Antithrombotic Therapy in Acute Ischemic Stroke. Multicenter Acute Stroke Trial — Italy (MAST-I). In: del Zoppo, G.J., Mori, E., Hacke, W. (eds) Thrombolytic Therapy in Acute Ischemic Stroke II. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78061-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-78061-5_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56442-3
Online ISBN: 978-3-642-78061-5
eBook Packages: Springer Book Archive